Reduction in Size of Prolactin-secreting Tumours in Men Treated with Pergolide

Overview

Journal Br Med J (Clin Res Ed)

Specialty General Medicine

Date 1982 Aug 14

PMID 6809126

Citations 3

Authors

P Kendall-Taylor

K Hall

D G Johnston

R W Prescott

Affiliations

Soon will be listed here.

Abstract

The effect of pergolide mesylate was studied in two previously untreated men with large prolactinomas and exceptionally high prolactin concentrations. The study was designed to determine whether pergolide would be effective in alleviating symptoms, correcting hormonal abnormalities and shrinking the tumour. Starting with 50 micrograms daily the dose of pergolide was slowly increased over 10 weeks to 1 mg once daily, when repeat assessment was performed. Both patients reported complete relief of symptoms, with no side effects. Serum prolactin concentration was suppressed to normal in both subjects, and evidence to suggest tumour shrinkage was observed. Pergolide appears to be effective treatment for men with large prolactinomas.

Citing Articles

Medical management of prolactin-secreting pituitary adenomas.

Molitch M Pituitary. 2003; 5(2):55-65.

PMID: 12675502 DOI: 10.1023/a:1022375429083.

Pergolide as primary therapy for macroprolactinomas.

Orrego J, Chandler W, Barkan A Pituitary. 2002; 3(4):251-6.

PMID: 11788013 DOI: 10.1023/a:1012836331506.

Effectiveness of pergolide mesylate in long term treatment of hyperprolactinaemia.

Franks S, Horrocks P, Lynch S, BUTT W, London D Br Med J (Clin Res Ed). 1983; 286(6372):1177-9.

PMID: 6404378 PMC: 1547416. DOI: 10.1136/bmj.286.6372.1177.

References

George S, Burrow G, Zinman B, EZRIN C . Regression of pituitary tumors, a possible effect of bromergocryptine. Am J Med. 1979; 66(4):697-702. DOI: 10.1016/0002-9343(79)91187-2. View

Lemberger L, CRABTREE R . Pharmacologic effects in man of a potent, long-acting dopamine receptor agonist. Science. 1979; 205(4411):1151-3. DOI: 10.1126/science.382359. View

McGregor A, Scanlon M, Hall R, Hall K . Effects of bromocriptine on pituitary tumour size. Br Med J. 1979; 2(6192):700-3. PMC: 1596246. DOI: 10.1136/bmj.2.6192.700. View

Lemberger L, Crabtree R, Callaghan J . Pergolide, a potent long-acting dopamine-receptor agonist. Clin Pharmacol Ther. 1980; 27(5):642-51. DOI: 10.1038/clpt.1980.91. View

Kleinberg D, Lieberman A, Todd J, Greising J, Neophytides A, Kupersmith M . Pergolide mesylate: a potent day-long inhibitor of prolactin in rhesus monkeys and patients with Parkinson's disease. J Clin Endocrinol Metab. 1980; 51(1):152-4. DOI: 10.1210/jcem-51-1-152. View